

Ref: FOI/GS/ID 8544

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

27 October 2023

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Lung cancer.

You asked: All questions are shown as received by the Trust.

Q1. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- a. ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)*
- b. Amivantamab*
- c. Atezolizumab Monotherapy*
- d. Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel*
- e. Dabrafenib + Trametinib*
- f. Docetaxel monotherapy or in combination with Carboplatin/Cisplatin*
- g. Durvalumab*
- h. Gemcitabine*
- i. Nitedanib + Docetaxel*
- j. Nivolumab*
- k. Osimertinib*
- l. Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)*
- m. Paclitaxel*
- n. Pembrolizumab Monotherapy*
- o. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)*
- p. Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)*
- q. Pemetrexed + Platinum (Carboplatin/Cisplatin)*
- r. RET Inhibitors (Pralsetinib, Selpercatinib)*
- s. Sotorasib*
- t. Tepotinib*
- u. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin*
- v. Other active systemic anti-cancer therapy*
- w. Palliative care only*

Q2. Of all the NSCLC patients treated with nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with nivolumab?

Q3. Does your trust/health board participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each active trial and the number of patients taking part.

Trust response:

1.

a.	7
b.	0
c.	2
d.	1
e.	2
f.	1
g.	2
h.	0
i.	2
j.	1
k.	25
l.	3
m.	0
n.	22
o.	1
p.	8
q.	4
r.	1
s.	2
t.	0
u.	10
v.	11
w.	15

2. No surgery planned or undertaken.

3. We do not have any trials for NSCLC which are currently recruiting, the ones below are in follow up:

IRAS	Short Title	Recruited
183975	PEARLS pembrolizumab as adjuvant treatment for lung cancer	2
278270	Osimertinib with or without chemotherapy in EGFR positive NSCLC	1
279531	GO41854 - Atezolizumab plus Tiragolumab vs Durvalumab in NSCLC	1